Debut Secures $20 Million to Revolutionize AI-Driven Skin Care Innovations

In a significant stride towards advancing skincare technology, Debut, a frontrunner in biotechnology beauty, has successfully raised $20 million in investment aimed at bolstering its AI-based ingredient discovery platform. This funding is set to propel the company's mission to lead in skin longevity innovation while expanding its formulation business across the United States and Asia.

The primary goal of this investment is to facilitate the discovery of next-generation skincare ingredients that effectively target the 14 hallmarks of aging. With this capital, Debut plans to provide its global beauty partners with the means to harness cutting-edge biotech ingredients and formulations, each married to distinctive claims. Furthermore, this advancement will allow beauty brands at all stages of development to outsource their formulation innovations with unprecedented speed, at scale, and without the significant upfront research and development costs typically associated with biotech.

Joshua Britton, PhD, the Founder and CEO of Debut remarked, "Our focus is steadfast on remaining at the forefront of skincare innovation, making advanced biotech accessible to every beauty brand with top-performing and uniquely differentiated ingredients. This funding enhances our capacity to screen over 50 billion ingredients, exploring the 99.999 percent of unknown molecules that have the potential to optimize skin health and drive skin longevity."

The predictive strength of Debut's proprietary datasets related to skin health has recently surpassed those available publicly, achieving an impressive 99 percent data consistency compared to the 85 percent typical in public datasets. Britton elaborated, “This means we can predict superior ingredients more rapidly through our best-in-class models developed over several years. We are excited about pursuing novel chemical entities (NCEs) rather than merely chasing pre-existing natural ingredients, which represents a new frontier in skin health innovation while supporting the growth of beauty brands.”

Debut’s fundraising comes during a period marked by increased caution among investors, yet the company is optimistically set to enter the Asian market, which is characterized by high-performance skincare and advanced formulations. According to Britton, “The combination of AI with a profound understanding of skin biology allows us to craft custom formulation solutions tailored for various geographies in ways that were previously unachievable.” Debut’s expansion in Asia will commence in Singapore, where they will collaborate with leading brands to formulate bespoke ingredients and formulations focused on skincare longevity.

The recent funding round saw participation from notable firms such as Fine Structure Ventures, EDBI, Wealthberry, BOLD (the venture fund associated with L'Oréal), GS Futures, Sandbox Industries, and Material Impact, among several others.

About Debut

Debut is pioneering the future of beauty via innovative AI and biotechnology, focusing on high-efficacy, scientifically-discovered ingredients and formulations that advance the industry. The company is renowned for delivering clinically proven and sustainably sourced ingredients that prioritize maximum effectiveness. Recognized as one of TIME100's Most Innovative Companies in 2025, Debut is reshaping standards within the beauty sector, centering on performance, potency, and purity. By continuously redefining the limits of skincare formulation, Debut aims to ensure that everyone can achieve optimal skin health through revolutionary biotech innovations.